Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The FDA's written response to the company's Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The HARMONIC trial is a randomized, double-blind, placebo-controlled study assessing LP-300 in combination with standard platinum-based chemotherapy in never-smoker patients with advanced lung adenocarcinoma who have progressed on tyrosine kinase inhibitor therapy. By narrowing the target population to those with the EGFR exon 21 L858R mutation, Lantern aims to leverage its AI-driven RADR platform to identify patients most likely to benefit, potentially increasing the trial's efficiency and success probability.
According to the company, the FDA's support marks a significant milestone for the LP-300 program and underscores the potential of precision oncology approaches in addressing unmet medical needs in non-small cell lung cancer. Never-smoker lung cancer, particularly with EGFR mutations, represents a distinct clinical entity with limited treatment options after TKI failure. LP-300, a cisplatin/ethacraplatin analog, is designed to overcome resistance mechanisms common in this population.
Lantern Pharma is a clinical-stage precision oncology company leveraging artificial intelligence and machine learning through its proprietary RADR platform to transform cancer therapy development. The company's pipeline includes LP-184 for solid tumors and LP-284 for hematologic malignancies, in addition to LP-300. Lantern also operates Starlight Therapeutics, a wholly owned subsidiary focused on pediatric CNS cancers, and has recently commercialized withZeta.ai, a multi-agentic AI co-scientist platform available as a subscription for the global biomedical community.
This development highlights the growing role of AI in drug development and regulatory strategy, as Lantern continues to refine its clinical programs based on data-driven insights. The company is headquartered in Dallas, Texas, with an AI Center of Excellence in Bengaluru, India. For more information, visit the company's newsroom at https://ibn.fm/LTRN.
